Comparison of Telmisartan a blood pressure lowering agent with other blood pressure lowering agents on its effects on insulin sensitivity, inflammation and vascular function in patients of type 2 diabetes with high blood pressure : an open label interventional study

Comparison of telmisartan with other anti-hypertensives on insulin sensitivity, inflammatory markers and vascular endothelial function in patients of T2DM with hypertension: an open-label interventional study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051878

Enrollment

Registered

2023-04-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Telmisartan 40mg: Telmisartan is given 40mg orally once daily for 3 months as per the standard treatment guidelines in patients of T2DM newly diagnosed with hypertension Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: 18-75 years of age SBP >140 mmHg DBP >90mmHg Diagnosed case of T2DM HbA1c between 7% and 10% Patients on metformin and /or DPP4 inhibitors

Exclusion criteria

Exclusion criteria: Pregnancy lactation T1DM Patients with heart failure ischemic stroke hemorrhagic stroke Traumatic brain injury malignancy patients on steroids immunosuppressants over a long time patients on exogenous insulin patients on mental and immune system disorders

Design outcomes

Primary

Measure	Time frame
To compare the effect of telmisartan with other anti hypertensives on insulin resistance in terms of HOMA IR valuesTimepoint: Baseline and after three months	—

Secondary

Measure	Time frame
compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory marker CRPTimepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory markers IL 6Timepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory markers TNF alphaTimepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of vascular endothelin 1Timepoint: Baseline and after 3 months	—

Measure

Time frame

compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory marker CRPTimepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory markers IL 6Timepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of inflammatory markers TNF alphaTimepoint: Baseline and after 3 months;To compare the effect of telmisartan with other anti-hypertensives on the levels of vascular endothelin 1Timepoint: Baseline and after 3 months

—

Countries

India

Contacts

Public ContactDr Simi Bridjit Gomaz

AIIMS Jodhpur

sidhurimple@yahoo.com09784525975

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026